![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessHydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
Specificity remains a major challenge to current therapeutic strategies for cancer. Mutation associated neoantigens (MANAs) are products of genetic alterations, making them highly specific therapeutic targets....
-
Article
Open AccessThe rapid and highly parallel identification of antibodies with defined biological activities by SLISY
The therapeutic applications of antibodies are manifold and the emergence of SARS-CoV-2 provides a cogent example of the value of rapidly identifying biologically active antibodies. We describe an approach cal...
-
Article
Open AccessStructural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
Chimeric antigen receptor (CAR) T cells have emerged as a promising class of therapeutic agents, generating remarkable responses in the clinic for a subset of human cancers. One major challenge precluding the ...